Pharma Focus Asia

Ligand Pharmaceuticals Develops Novel Ohtuvayre™ for the Treatment of Chronic Obstructive Pulmonary Disease

Ligand Pharmaceuticals has developed Ohtuvayre™ (ensifentrine), the first inhaled treatment with a novel mechanism for chronic obstructive pulmonary disease (COPD) in over 20 years.

Ohtuvayre is a groundbreaking selective dual inhibitor of the enzymes phosphodiesterase 3 and phosphodiesterase 4 (PDE3 and PDE4). It combines bronchodilator and non-steroidal anti-inflammatory effects in a single molecule.

Administered directly to the lungs using a standard jet nebuliser, Ohtuvayre eliminates the need for high inspiratory flow rates or complex hand-breath coordination.

In both the ENHANCE-1 and ENHANCE-2 trials, Ohtuvayre met the primary endpoint, showing statistically significant and clinically meaningful improvements in lung function.

Currently, a fixed-dose combination of ensifentrine and glycopyrrolate, a long-acting muscarinic antagonist (LAMA), is under development for the maintenance treatment of COPD. Ensifentrine also holds potential for treating non-cystic fibrosis bronchiectasis, cystic fibrosis, asthma, and other respiratory diseases.

Chronic obstructive pulmonary disease encompasses a group of conditions that cause airflow blockage and breathing-related issues, such as emphysema and chronic bronchitis. Over 390 million people worldwide live with COPD.

Common symptoms include increased shortness of breath, frequent coughing (with and without mucus), wheezing, chest tightness, and unusual tiredness. Approximately 50% of COPD patients experience almost daily symptoms. While there is no cure for COPD, and despite existing treatment options, it remains the third leading cause of death globally.

 

magazine-slider-imageCytiva - Supor Prime filtersMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference